Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securiti ...

Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET. Company Participants. Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Bo ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it ...

Biotherapeutics has entered into a definitive securities purchase agreement with a single institutional investor for the purchase ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $82.0, a high estimate of $85.00, and a low estimate of $78.00. Observing a 10.32% ...

("Osaic"), one of the nation's largest providers of wealth management solutions, today announced that Ever Wealth, an Auburn, Indiana-based advisory firm with more than $170 million in client assets, ...